Press Room

RDD Europe 2023

Start
Tuesday, May 02, 2023 - 09:00
End
Friday, May 05, 2023 - 17:06
Location: Antibes, France
Booth Number: Table #20
Drug Delivery Formulation | 四色AV

四色AV will be exhibiting at from May 2-5. Don鈥檛 miss the chance to speak with our experts in the Inspiring Dry Powder Inhalation Knowledge Space and learn how our development and manufacturing services for inhalation and nasal - integrated on a single site - can support in bringing your product to market.

Find us at the Blue Knowledge Space - Inspiring Dry Powder Inhalation - Table #20

schedule a meeting

On May 3rd, don鈥檛 miss the joint workshop with 四色AV and H&T Presspart听

Title - 鈥淚ntegrated Development for Capsule-based DPIs - Solving New Challenges鈥

Presenters:

  • Susana Saldanha, M.Sc. - R&D Manager, Formulation Development, 四色AV
  • Jo茫o Pereira, M.Sc. - R&D Analytical Development, 听Analytical Manager, 四色AV
  • Mirjam Kobler Ph.D. - 听Global Business Development Manager, H&T Presspart听

Abstract:

This workshop will address the most relevant aspects of DPI development covering formulation to device development, as well as process optimization and analytical characterization. 听The most common challenges expected at each stage will also be highlighted. A data-based development approach will be applied using risk analysis and structured experimental design based on various case studies, for different development stages, including process optimization and scale-up activities. Starting with a review on the design and development of a highly efficient capsule-based device, the participants will further learn how to use tools to prepare and design development plans to achieve optimal performance from different formulation strategies to drug-device combinations. Case studies will be presented on the interplay of carrier-based and carrier-free formulations, with a newly designed device. The higher focus will be placed on the hurdles of composite particles formulation and process development as well as capsule filling of said challenging formulations. 听Unit operations such as spray drying and capsule filling will be covered during this workshop.

On May 4th, don鈥檛 miss the POP Session 鈥 鈥淧osters on the podium鈥 with Patricia Henriques, M.Sc.

Title - Benchmarking of Particle Engineering Strategies for Nasal Powder Delivery: Characterization of Nasal Deposition using the Alberta Idealized Nasal Inlet

Abstract:

Powder formulations of a drug and mucoadhesive polymer have increased residence time in the nasal cavity and can be manufactured by blending, spray-drying or agglomeration of primary particles into chimeral agglomerates (CA). While spray-drying allows particle size control and generation of amorphous solid dispersions, blending is simpler and CA should allow faster dissolution after breakup into smaller particles. The objective of this study was to characterize nasal deposition and benchmark nasal powders manufactured by different particle engineering strategies, namely spray dried microparticles (SDM), CA and blends, using the Alberta Idealized Nasal Inlet (AINI). The AINI method conditions were firstly optimized by selecting appropriate angle of actuation and flow rate. Then, six different formulations prepared with distinct polymers and particle engineering strategies were evaluated.

On May 5th, don鈥檛 miss the Podium Presentation with Eunice Costa R&D Director, Inhalation & Advanced Drug Delivery听

Title - 鈥淎ddressing challenges in high dose dry powder inhalation: formulation and device鈥

Abstract:

High dose delivery to the lungs is gaining momentum to address a diversified array of diseases being treated via respiratory drug delivery, comprising a range of drug classes, spanning from less potent small molecules to biologics. Dry Powder Inhalers (DPI) are the dosage form of choice for delivering high payloads to patients. Still there are opportunities for improvement in terms of ensuring that the formulation addresses the pharmacokinetics needs of the specific drug and indication, in close integration with the device, while ensuring delivery efficiency and safety.听
Herein, different high dose delivery platform approaches are discussed in terms of relative advantages and potential pitfalls, followed by some exemplary case-studies: from small molecules to biologics: development of high dose crystalline formulations and high dose spray dried proteins, as well as implementation of a DPI device suitable for cohesive high dose formulations.听

Two posters will also be presented:

  • Title - In Vitro Methodologies for the Screening of Nasal Powders: Polymer-based Formulations听
    Presenter: Patricia Henriques, M.Sc. 鈥 University of Coimbra, 四色AV
  • Title - Expediting spray dried DPI formulation via the use of PAT
    Presenter: Maria In锚s Lopes, M.Sc. 鈥 University of Lisbon, 四色AV

and get to know more about our unique range of particle engineering technologies for Inhalation & Nasal such as jet milling, wet milling and spray drying.

Let鈥檚 discuss your project together.

schedule a meeting

Find more about .

Also in the Press Room

See All

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024